By Armen Hareyan on October 1, 2007 - 9:52pm 
for eMaxHealth
for eMaxHealthMay Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients
Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for a 300mg tablet of the antiplatelet PLAVIX
Source:
Sanofi Aventis "LIKE" eMaxHealth for more updates on this topic in Facebook!
eMaxHealth welcomes your comments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
